A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults

Study Identifier:
D7420C00003
ClinicalTrials.gov Identifier:
NCT06173596
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN2080
  • Drug: Itraconazole
  • Drug: Fluconazole (AxMP)
  • Drug: Carbamazepine (AxMP)
Date
Jan 2024 - Apr 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years
Requirements Information
Sex
Female & Male
Age
18 - 55 Years

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN2080
  • Drug: Itraconazole
  • Drug: Fluconazole (AxMP)
  • Drug: Carbamazepine (AxMP)
Date
Jan 2024 - Apr 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years years
Requirements Information

Protocol Summary

The primary objectives of this study are to determine the effect of multiple doses of itraconazole on the single dose PK of ALXN2080, to determine the effect of multiple doses of fluconazole on the single dose PK of ALXN2080 (optional), and to determine the effect of multiple doses of carbamazepine on the single dose PK of ALXN2080.

Trial Locations

Location
Status
Location
Research Site
Ruddington, United Kingdom, NG11 6JS
Status
N/A